Cardiovascular Outcomes with Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED a randomised trial

“A Time to Tear Down and a Time to Mend” – The Role of Eicosanoids in Atherosclerosis

REDUCE-IT, biomarkers, and confirmation bias: are we missing the forest for the trees?

Omega-3 fatty acids for Cardiovascular Event Lowering

Eicosapentaenoic acid improves endothelial nitric oxide bioavailability via changes in protein expression during inflammation

Do patients benefit from omega-3 fatty acids?

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction with Icosapent Ethyl

Omega-3 Fatty Acids Influence Membrane Cholesterol Distribution and Crystal Formation in Models of Atherosclerosis